Markus Glatzel
Markus Glatzel studied medicine at the Universities of Ulm and Freiburg receiving his MD in 1997. He completed his pathology/neuropathology training at the University of Zurich and also received postdoctoral training at the University of Zurich. He established his research group at the University Hospital Zurich. Since 2006, he is Professor of Neuropathology and Director of the Institute of Neuropathology University at Medical Center, where he also served as the Chairman of the Diagnostic Center from 2012 to 2025. His scientific interest lies in translational neuropathology focusing on pathogen-caused neurological diseases and dementia. Within the FOR 5705 his interest lies in translational neuropathological aspects of neurodegeneration seen in neuroimmunological diseases.Please provide a narrative bio sketch of yourself (max. 200 words) ending with a sentence about your focus within NeuroFlame.
Publications
Ligands binding to the prion protein induce its proteolytic release with therapeutic potential in neurodegenerative proteinopathies. Linsenmeier L., Mohammadi B., Shafiq M. et al. Sci Adv. 7, eabj1826 (2021).
A multifactorial model of pathology for age of onset heterogeneity in familial Alzheimer's disease. Sepulveda-Falla D., Chavez-Gutierrez L., Portelius E. et al. Acta Neuropathol. 141, 217-233 (2021).
Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Matschke J., Lütgehetmann M., Hagel C. et al. Lancet Neurol. 19, 919-929 (2020).
Familial Alzheimer's disease-associated presenilin-1 alters cerebellar activity and calcium homeostasis. Sepulveda-Falla D., Barrera-Ocampo A., Hagel C. et al. J Clin Invest. 124, 1552-67 (2014).
High molecular mass assemblies of amyloid-β oligomers bind prion protein in patients with Alzheimer's disease. Dohler F., Sepulveda-Falla D., Krasemann S. et al. Brain. 137, 873-86 (2014).
Links
Institution
Hamburg
